FindTrial
Sign In

Aspirin Placebo

DRUG5 trials

Sponsors

Columbia University, Bayer, Genentech, Inc., Icahn School of Medicine at Mount Sinai, Montreal Heart Institute

Conditions

Cardiovascular DiseasesDiabete Type 2Peripheral Artery DiseasePrevention & ControlStrokeType 2 Diabetes

Phase 3

Warfarin Versus Aspirin Recurrent Stroke Study
CompletedNCT00027066
Columbia UniversityStroke
Start: 1993-06-30End: 2001-11-30Target: 2206Updated: 2011-06-17
Rivaroxaban for the Prevention of Major Cardiovascular Events in Coronary or Peripheral Artery Disease
CompletedNCT01776424
BayerPrevention & Control
Start: 2013-02-28End: 2021-06-15Updated: 2022-11-28
A Study of the Efficacy and Safety of Alteplase in Participants With Mild Stroke
TerminatedNCT02072226
Genentech, Inc.Stroke
Start: 2014-05-31End: 2017-03-22Updated: 2018-07-03
Comparative Efficacy of Ticagrelor Versus Aspirin on Blood Viscosity in Peripheral Artery Disease Patients With Type 2 Diabetes
CompletedNCT02325466
Icahn School of Medicine at Mount SinaiPeripheral Artery Disease, Type 2 Diabetes
Start: 2015-04-30End: 2018-05-04Updated: 2022-03-21
COLchicine and Non-enteric Coated Aspirin in the Cardiovascular Outcomes Trial of Patients With Type 2 Diabetes
RecruitingNCT05633810
Montreal Heart InstituteCardiovascular Diseases, Diabete Type 2
Start: 2022-12-21End: 2027-12-01Target: 10000Updated: 2026-03-10

Related Papers

Comparison of total event analysis and first event analysis in relation to heterogeneity in cardiovascular trials.
2025-06-09
Improving analysis of cognitive outcomes in cardiovascular trials using different statistical approaches.
2024-10-02
Health-related quality of life with rivaroxaban plus aspirin vs. aspirin alone in chronic stable cardiovascular disease: Cardiovascular Outcomes for People Using Anticoagulation Strategies (COMPASS) trial
European Heart Journal Open2024-08-311 citations
Results of the COMPASS Trial Analyzed Using Win Ratio Compared With Conventional Analytic Approaches.
2024-07-144 citations
Impact of Frailty on the Benefits of Dual Pathway Inhibition for the Secondary Prevention of Cardiovascular Events in the COMPASS Randomised Trial.
2024-06-226 citations
The Effects of Pantoprazole on Kidney Outcomes
Journal of the American Society of Nephrology2024-04-119 citations
The Cost-Effectiveness of Rivaroxaban Plus Aspirin Compared with Aspirin Alone in the COMPASS Trial: A US Perspective.
2023-12-286 citations
The cost-effectiveness of rivaroxaban with or without aspirin in the COMPASS trial.
2023-08-0110 citations
Total events and net clinical benefit of rivaroxaban and aspirin in patients with chronic coronary or peripheral artery disease: The COMPASS trial.
2023-01-147 citations
Health status and cognitive function for risk stratification in chronic coronary and peripheral artery disease
European Journal of Preventive Cardiology2022-11-2810 citations
Comparison of Investigator-Reported vs Centrally Adjudicated Major Adverse Cardiac Events
JAMA Network Open2022-11-2112 citations
Optimum Treatment Strategy in Chronic Coronary Syndromes: the New Trials vs the Current Guidelines
Rational Pharmacotherapy in Cardiology2021-11-031 citations
Mortality Benefit of Rivaroxaban Plus Aspirin in Patients With Chronic Coronary or Peripheral Artery Disease.
2021-07-0131 citations
Skeletonized vs Pedicled Internal Mammary Artery Graft Harvesting in Coronary Artery Bypass Surgery
JAMA Cardiology2021-06-1662 citations
Cardiovascular consequences of discontinuing low-dose rivaroxaban in people with chronic coronary or peripheral artery disease
Heart2021-05-219 citations
Risk stratification of cardiovascular complications using CHA<sub>2</sub>DS<sub>2</sub>-VASc and CHADS<sub>2</sub> scores in chronic atherosclerotic cardiovascular disease.
2021-05-035 citations
Rivaroxaban Plus Aspirin in Obese and Overweight Patients With Vascular Disease in the COMPASS Trial.
2021-02-0112 citations
Rivaroxaban for Prevention of Covert Brain Infarcts and Cognitive Decline
Stroke2020-09-2123 citations
Oral factor Xa inhibitors and risk of subdural hematoma: COMPASS trial results and meta-analysis.
2020-07-10
Post-Discharge Prophylaxis With Rivaroxaban Reduces Fatal and Major Thromboembolic Events in Medically Ill Patients
Journal of the American College of Cardiology2020-06-0161 citations

20 more papers not shown